期刊文献+

氯沙坦降压疗效及对内皮素和心钠素的影响 被引量:2

Therapeutic effect of losartan on hypertension and its effects on the plasma ET-1 and ANP
下载PDF
导出
摘要 目的 探讨氯沙坦的降压效果及对内皮素 (ET 1)及心钠素 (ANP)的影响。方法 对 78例高血压病患者分别用氯沙坦和依那普利治疗 ,记录 2 4h动态血压监测 (ABPM )和每日偶测血压的变化 ,测定治疗前后血浆ET 1、ANP水平变化。两组进行比较。结果 氯沙坦组降压作用同依那普利组比较 ,差异无显著性。氯沙坦组收缩压 (SBP)及舒张压 (DBP)的降压谷 峰 (T P)比值分别为 64 .4%和 60 .1%。两组血浆ET 1和ANP均降低。结论 氯沙坦是一种安全有效的降压药 ,服药后ET 1和ANP降低 。 Objective To investigate the efficacy of Losartan in reducing blood pressure and its effects on the plasma ET 1 and ANP.Methods Losartan and Enapril were administered respectively to seventy eight hypertensive patients.ABPM was recorded and blood pressure was measured every day.The plasma ET 1 and ANP were also measured before and after treatment.The two groups were compared.Results The efficacy of Losartan in reducing blood pressure was not significantly different from that of Enapril group.The ratio of trough:peak (T/P)of decompression of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in losartan group was 64.4% and 60.1%.The plasma ET 1 and ANP decreased significantly in both groups.Conclusion Losartan is a safe and effective antihypertension agent.ET 1 and ANP decreased after treatment,which is beneficial for hypertensive patients.
出处 《河北医药》 CAS 2002年第4期254-255,共2页 Hebei Medical Journal
关键词 高血压 氯沙坦 内皮素 心钠素 降压药 治疗 降压效果 hypertension Losartan ET 1 ANP
  • 相关文献

参考文献2

二级参考文献7

  • 1[1]Smith R D, Sweet C S, Golderg A I, et al. Losartan pota-ssium: A nonpeptide antagonist of angiotensin Ⅱ.Drugs Today, 1996,32(Suppl F):1-41.
  • 2[2]Crozier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation, 1995, 91:691-697.
  • 3[3]d'Uscio L V, Shaw S, Barton M, et al. Losartan but not verapamil inhibits angiotensin Ⅱ-induced tissue endothelin-1 increase: Role of blood pressure and endothelial function. Hypertension, 1998, 31(6): 1305-1310.
  • 4Loa L,Wagstaff J,Autona.Losartan potassium a review of itsphamacology,Clinical efficacy and tolerability in the managementof hypertension[].Drugs.1995
  • 5Stearns RA,Miller RR,Doss GA,et al.The metabolism of Dup753a nonpeptide angiotensin II receptor antagonist, by rat, monkeyand human liver slices[].Drug Metabolism and Disposition.1991
  • 6Othawa M,Takayama F,Saitoh K.Pharmacokinetics and biochem-ical efficacy after single and multiple oral administration of losartan,an orally active nonpeptide angiotensin II receptor antagonist[].Br J Clin Pharmacol.
  • 7Buruier M,Rutsdimann B,Nussberger J,et al.Salt dependent renal effects of an angiotensin II antagonist in healthy subjects[].ypertension.1993

共引文献11

同被引文献16

  • 1[1]Handke R,Jux C,Schranz D,et al.Transcatheter closure of perimembranous ventricular septal defects using umbrella devices.Catheter Cardiovasc Interv,2006,68:936-41.
  • 2[2]Singh A,Girotra S,Mehta Y,et al.Total intravenous anesthesia with ketamine for pediatric interventional cardiac procedures.J Cardiothorac Vasc Anesth,2000,14:36-9.
  • 3[3]Münte S,Münte TF,Kuche H,et al.General anesthesia for interventional neuroradiology:propofol versus isoflurane.J Clin Anesth,2001,13:186-92.
  • 4[4]Gayatri P,Suneel PR,Sinha PK,et al.Evaluation of propofol-ketamine anesthesia for children undergoing cardiac catheterization procedures.J Interv Cardiol,2007,20:158-63.
  • 5[5]Akin A,Esmaoglu A,Guler G,et al.Propofol and propofol-ketamine in pediatric patients undergoing cardiac catheterization.Pediatr Cardiol,2005,26:553-557.
  • 6[6]Barker N,Lim J,Amari E,et al.Relationship between age and spontaneous ventilation during intravenous anesthesia in children.Paediatr Anaesth,2007,17:948-55.
  • 7[7]Cavallero S,González GE,Puyó AM,et al.Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy.J Hypertens,2007,25:1940-50.
  • 8[8]Baertscli AJ,Adams JM,Sullivan MP.Acute hypoxemia stimulates ANP secretion in vivo.Am J Physiol,1998,255:1295-3000.
  • 9Cohn GS, Kittleson MM, Blumenthal RS,et al. Toward an improved diagnosis of the medabolic syndrome other clues to the presence of insulin resistance. Am J Hypertens, 2005,18: 1099-1103.
  • 10Guzkk TJ, West NEJ, Pillai R, et al. Nitric oxide modulates superoxide release and pemxynitrite formation in human blood vessels. Hypertention,2002, 39: 1088-1094.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部